CLINICAL_TRIALS
other
· 2025-05-30
Clinical Trial Update: Evaluation of Oral ORIN1001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) [Phase 1]
Summary
The Phase 1 clinical trial evaluating Orin1001 for idiopathic pulmonary fibrosis has been suspended, according to sponsor Orinove, Inc.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Orinove, Inc. | Conditions: Idiopathic Pulmonary Fibrosis | Phase 1 | Status: SUSPENDED